Sepsis/SIRS: Pathomechanisms and new therapeutic perspectives;Sepsis/SIRS: Pathomechanismen und therapeutische Ansatze

Anasthesiologie und Intensivmedizin

Volumn 37, Issue 7-8, 1996, Pages 386-403

  Koch, T ^a,b   Heller, S ^a  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

combined modality therapy; critical care; inflammation; septicaemia

Indexed keywords

ADENOSINE; ANTIBIOTIC AGENT; ANTIBODY; ANTICOAGULANT AGENT; ANTIOXIDANT; BRADYKININ ANTAGONIST; CYTOKINE; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTOXIN; ESTERASE INHIBITOR; ICOSANOID; NITRIC OXIDE; OXYGEN RADICAL; PROTEINASE INHIBITOR; QUININE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; XANTHINE;

HUMAN; INFLAMMATION; MORTALITY; PATHOPHYSIOLOGY; REVIEW; SEPSIS;

EID: 0029762368     PISSN: 01705334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Abraham E, Wiinderink R, Silvernwn H, for the TNF-nlplia Mab Sepsis Study Group: Efficacy and safety of monoclonal antibody to human tumour necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273 (1995) 934-941.
2. Anlonclli M, Bufi M, De Blasi RA, Crimi G, Conti G, Mattia C, Vivino G, Lenti L, Lombardi D, Dotta A, Pontieri G, Gasparetto A: Detection of leukotriene B4, C4 and their isomers in arterial, mixed venous blood and bronchoalveolar lavage fluid from ARDS patients. Intensive Care Med 15 (1989)296-301.
3. Arend WP: Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 88 (1991) 1445-1451.
4. Bagge L, Haglund O, Wallin R, Borg T, Modig J: Differences in coagulation and fibrinolysis after traumatic and septic shock in man. Scand J Clin Invest 49 (1989) 63-72.
5. Ball HA, Cook JA, Wise WC, Halushka PV: Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock. Intensive Care Med 12 (1986) 116-126.
6. Bein T, Pfeiffer M, Riegger.GAJ, Taeger K: Continuous intraarterial measurement of oxygénation during aerosolized prostacyclin administration in severe respiratory failure. N Engl J Med 331 (1994) 335-336.
7. Benzing A, Geiger K: Inhaled nitric oxide lowers pulmo-nary capillary pressure and changes longitudinal distribution of pulmonary vascular resistance in patients with acute lung injury. Acta Anaesthesiol Scand 38 (1994) 640-645.
8. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Täte RM, Sibbald \VJ, Kariman K, Higgins S, Bradley R, Metz CA, Harris TR, Brigham KL: High dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl JMed 317 (1987) 1565-1570.
9. Beutler B, Krocliin N, Milsark 1\V: Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232 (19S6) 977-980.
10. Bigatello LM, Ihirford WE, Kacmarek RM, Roberts JD Jr, Zapol WM: Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome; effects on pulmonary hemodynamics and oxygénation. Anesthesiology 80 (1994) 761-770.
11. Bitterman IT, Aoki N, Lefer AM: Anti-shock effects of human Superoxide dismutase in splanchnic artery occlusion (SAG) shock. Proc Soc Exp Biol Med 188 (1988) 265-271.
12. Bone RC, Fisher CJJr, Clemmcrb TP, Slotman GJ, Metz GA, Balk RA: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317 (1987) 653-358.
13. Bone RC, Slotman GJ, Maunder R, Silvennan H, Hycrs Tli M, Kcrstein MD, Ursprung JJ: Randomized doubleblind, multicenter study of prostaglandin El in patients with the adult respiratory distress syndrome. Chest 96 (1989) 114119.
14. Bone RC: Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med 114 (1991) 332-333.
15. Bone RC: The pathogenesis of sepsis. Ann Intern Med 115(1991)457-469.
16. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knatis WA, Schein RMH, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101 (1992) 1644-1655.
17. Bottaro D, Sliepro D, Peterson S, Hechtman HB: Serotonin, norepinephrine, and histamine mediation of endothelial cell barrière function in vitro. J Cell Physiol 128 (1986) 189-194.
18. Bratliwaite C, Slotman G, Fricdman B, PribbleJ, Shelly M, SadoffJ, OpalS, Balk R, Dliainant J, Fisher C, Thompson R, Phase III rhlL-Ira Sepsis Syndrome Study Group: The effect of recombinant human interleukin receptor antagonist on organ dysfunction and survival in postoperative surgical patients with sepsis syndrome. Shock (Suppl) 3 (1995) 63.
19. Breil I, Koch T, Goldberg S, Neuhof H, van Ackern K: Influence of E$2 receptor antagonists on bradykinin-induced vasodilation and edema formation in isolated rabbit hindlimbs. Inflamm Res 44 (1995) 212-216.
20. Breil I, Koch T, Belz M, Neuhof M, van Ackern K: Effects of bradykinin, histamine and serotonin on pulmonary vascular resistance and permeability. Acta Physiol Scand (in press).
21. Breil I, Koch T, Heller A, Schlotzer E, Grünen A, van Ackern K, Neuhof H: Alterations of n-3 fatty acid composition in lung tissue after short-term infusion of fish oil emulsion attenuates inflammatory vascular reaction. Crit Care Med (in press).
22. Broner CW, Shcnep JL, Stidham GL, Stokes DC, Hildncr \VK: Effect of scavengers of oxygen-derived free radicals on mortality in endotoxin challenged mice. Crit Care Med 16(1988)848-851.
23. Brown AJ, Pang E, Roberts DCK: Persistent changes in the fatty acid composition of erythrocyte membranes after moderate intake of n-3 polyunsaturated fatty acids: study design implications. Am J Clin Nut 54 (1991) 668-673.
24. Diirhop KE, Selig W Al, Malik AB: Monohydroxyeicosatetraenoic acids (5-HETE and 15-HETE) induce pulmonary vasoconstriction and edema. Circ Res 62 (1988) 687-698.
25. Burton JL: Dietary fatty acids and inflammatory skin disease. Lancet 7 (1989) 27-30.
26. Calamlra T, Glatiser MP, Sclicllekcns J, Vcrhocf J: Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective double-blind, randomized trial. J Infect Dis, 158 (1988) 312-319.
27. Casals-StenzelJ: Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock. Eur J Pharmacol 135 (1987) 117-122.
28. Chilian FH, Paid M, Fonteh AN, Hubbard \VC, Triggiani M: Dietary n-3 fatty acid effects on neutrophil lipid composition and mediator production. Influence of duration and dosage. J Clin Invest 91 (1993) 115-122.
29. Christman J\V, Holden EP, Black\vell TS: Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 23 (1995) 955-963.
30. Cobb JP, Citnnion RE, Damier RL: Nitric oxide as a target for therapy in septic shock. Crit Care Med 21 (1993) 1261-1263.
31. Croset M, Bayou Y, Lagarde M: Incorporation and turnover of eicosapentaenoic and docosahexaenoic acids in human blood platelets in vitro. Biochem J 281 (1992) 309-316.
32. Culpeppcr JA, Lee F: Regulation of IL 3 expression by glucocorticoids in clonel murine T Lymphocytes. J Immunol. 135(1985)3191.
33. Davidson FE, Dennis EA, Powell M, GlennyJRJr: Inhibition of phospholipase A2 by Lipcortins" and calpactins. An effect of binding substrate phopholipids. J Biol Cheni. 262 (1987) 1698-1705.
34. Davis JM, Meycr JD, Baric PS, Yurl RW, Dnlianey R, Dinccn P, Shires GT: Elevated production of neutrophil leukotriene B4 precedes pulmonary failure in critically ill surgical patients. Surg Gynecol Obstet 170 (1990) 495-500.
35. DhainaiitJ-F A, Tamilian A, Le Tulzo Y, Schlemmer B, SoletJ-P, WolffM, Holzapfel L, Zciii F, Drey fuss D, MiraJP, de Vathaire F, Guinot P, the BN 52021 Sepsis Study Group: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22 (1994) 1720-1728.
36. Dhainaut JF, Tamilian A, Guinot Pit, Sepsis Study Group: F.A.F. Antagonist (BN52021) in Severe gram-negative Sepsis. Shock (Suppl) 3 (1995) 152.
37. Dinarello CA, Thompson RC: Blocking IL-1: Interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today 12 (1991) 404-410.
38. Dinarello CA, \VolffSM: The role of interleukin-1 in disease. N EnglJ Med 328 (1993) 106-113.
39. Eichackcr PQ, Huffman WD, Farese A, Damier RL, Sitffredini AF, Waisman Y, Banks SM, Moiiginis T, Wilson L, Rotltlein R: Leukocyte CD 18 monoclonal antibody worsens endotoxemia and cardiovascular injury in canines with septic shock. J Appl Physiol 74 (1993) 1885-1892.
40. Ember JA, Johanson NL, Hugli TE: Designing synthetic superagonists of C3a anaphylatoxin. Biochemistry 30 (1991) 3603-3612.
41. Evans T, Carpenter A, Knidcrman.H, CohenJ: Evidence of increased nitric oxide production in patients with sepsis syndrome. Circ Shock 41 (1993) 77-81.
42. Exley AR, Cohen J, Biiiirman W, Owen R, Hanson G, Liunley J, Aulakli JM, Bo Amer M, Riddell A, Stephens S,\ Perry M: Monoclonal antibody to TNF in severe septic shock. Lancet 335 (1990) 1275-1277.
43. Fearon DT: Anti-inflammatory and immunosuppressive effects of recombinant soluble complement receptors. Clin. Exp. Immunol. 86 (1991) 43-46.
44. Fernändez-Gallardo S, Onega P, Priego JG, de CasaJitana F, Sunkel C, Sänchez-Crespo M: Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies. J. Pharmacol. Exp. Ther. 255 (1990) 34-39.
45. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hauler EG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257 (1992) 387389.
46. Fischer S, Weber P: Prostaglandin 13 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 307 (1988) 168-171.
47. Fisher E, Marano MA, van Zee KJ, Rock CS, Hawes AS, Thompson WA: Interleukin-1 receptor blockade improves survival and hemodynamic perfomance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89 (1992) 1551.
48. Fisher CJ, Jr. Opal SM, Dhaiiiant J-F, Stephens S, Zimmerinan JL, Nightingale P, Harris SJ, Schein RM, Panacek EA, Vincent JL: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21 (1993) 318-327.
49. Fisher CJ Jr, Dlwinant J-F, Opal SM, for the Phase III rhlL-lra Sepsis Syndrome Study Group: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome; results from a randomized, double-blind, placebo controlled trial. JAMA 271(1994) 1836-1843.
50. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalanos MA: Initial evaluation of human recombinant interleukin receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo controlled multicenter trial. Crit Care Med 22 (1994) 12-21.
51. Fisher CJ, Marra MN, Palardy JE, Marchbanks CR, Scott R\V, Opal SM: Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study. Crit Care Med 22 (1994)553-558.
52. FletcherJR, DiSimone AG, Earnest MA: Platelet activating factor antagonist, BN52021, improves survival and inhibits eicosanoid production in endotoxemia. Ann Surg 211 (1990) 312-316.
53. Ford-Hntchinson AW: Innovations in drug research: inhibition of thromboxane and leukotrienes. Clin Exp Allergy 21(1991)272-285.
54. Fretland DJ, Widomski D, Tsai DS, Zemaitis JM, Levin St, Djuric St W, Shone RL, Gaginella TS: Effect of leukotriene B4 receptor antagonist SC-41930 on colonie inflammation in rat guinea pig and rabbit. J Pharmacol Exp Therap 255 (1990) 572-583.
55. Gillis, CN: Pulmonary extraction of PGEi. Am Rev Respir Dis 137 (1988) 1-4.
56. Goode HF, Webster NR: Free radicals and antioxidants in sepsis. Crit Care Med 21 (1993) 1770-1776.
57. Goris RIA, Doekhorst TPA, Nnytinck JKS, Gimbere JSF: Multiple-organ failure: generalized autodestructive inflammation? Arch Surg 120 (1985) 1109-1115.
58. Goris RJA, Boekholtz WKF, van Bebber IPT, Nnytinck JKS, Schillings PHM: Multiple-organ failure and sepsis without bacteria. Arch Surg 121 (1986) 897-901.
59. Greenman RL, Schein RMH, Martin MA, Wenzel RP, Maclntyre NR, Emmanuel G, Climel H, Kohler RB, McCarthy M, PlouffeJ, RussellJA, XOMA Sepsis Study Group: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266 (1991) 10971102.
60. Grimminger F, NcuhofH: Bildung und Wirkung von Lipidmediatoren in der Mikrozirkulation. In: Stodtmeister R, Pillunat LE (Hrsg.) Mikrozirkulation in Gehirn und Sinnesorganen. Enke Verlag Stuttgart 1991, p. 22-40.
61. Grimminger F, Mayser P, Papavassilis C, Tliomas M, Schlotzer E, Heuer K-U, Führer D, Hinscli K-D, Walmralh D, Schill \V-B, Seeger \V: A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute extended guttäte psoriasis. Clin Investig 71 (1993) 634643.
62. Groeneveld ABJ: Septic shock and multiple organ failure: treatment with haemofiltration? Intensive Care Med 16 (1990) 489-490.
63. Hack CE, Vorman 111, Eisele B, Keinecke HO, Nitijens JH, Eerenberg AJM, Ogilvie A, Strack van Schindel RJM, Detvos U, Tliijs LG: Cl-esterase inhibitor substitution in sepsis. Lancet 339 (1992) 378.
64. Hang CE, Calvin RB, Delmonico FL, Auchincloss H, Jr, Tolkoff-Rubin N, Preffer FL, Rotlilein R, Norris S, Scharschmidt L, Cosimi AB: A. Phase I trial of immunosuppression with Anti-ICAM-1 (CD 54) mAb in renal allograft recipients. Transplantation 55 (1993) 766-773.
65. Havell EA: Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 143 (1989) 2894-2899.
66. Herndon DN, Abston S, Stein MD: Increased thromboxane B2 levels in the plasma of burned and septic patients. Surg Gynecol Obstet 159 (1984) 210-213.
67. Hershman MJ, Pietsch JD, Traclttcnberg L, Mooney THR, Shields RE, Sonnenfeld G: Protective effects of recombinant human tumor necrosis factor alpha and interferon gamma against surgically stimulated wound infection in mice. Br J Surg 76 (1989) 1282-1286.
68. HillJ, Lindsay TF, Ortiz F, Yeh G, Hechtman HD, Moore FD Jr: Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemiareperfusion in the rat. J. Immunol. 149 (1992) 1723-1728.
69. Hinslww L, Peduzzi P, Young E, Sprung C, Shatney C, Sheagren J, Wilson M, Haakenson C: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317 (1987) 659-665.
70. Hock CE, Beck LD, Papa LA: Peptide leukotriene receptor antagonism in myocardial ischemia and reperfusion Cardiovasc Res 26 (1992) 1206-1211.
71. Hoffmann H, HatherillJR, CrowleyJ, Fritz H, Weis M, Aigner F, Ishizaka A, Raffin TA, Schildberg FW: Early posttreatment with pentoxifylline or dibutyryl cAMP attenuates Escherichia coli-induced acute lung injury in guinea pigs. Am Rev Respir Dis 143 (1991) 289-293.
72. Huffman WD, Natanson C: The role of endotoxin in bacterial septic shock. In:Yearbook of Intensive Care and Emergency Medicine 1993, Vincent JL (Ed). Berlin Heidelberg New York, Springer Verlag, 1993, p. 49-63.
73. Hollenberg SM, Cininion RE, Zimmerberg J: Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. Am J Physiol 264 (1993) H660-3.
74. Ishizaka A, Wu Z, Stephens KE, Harada H, Hague RS, O'Hanley PT, Raffin TA: Attenuation of acute lung injury in septic guinea pigs by pentoxifylline. Am Rev Respir Dis 138 (1988) 376-382.
75. Jocliiim M, Gippner-Steppert C, Machleidt \V, Fritz H: The role of phagocyte proteinases and proteinase inhibitors in multiple organ failure. Am J Respir Crit Care Med 150 (1994) 123-130.
76. Kadowitz PJ, Ilymann AL: Pulmonary vascular response to histamine in sheep. Am J Physiol 244 (1983) H423H428.
77. Kips JC, Joos GF, de Lepeleire I, Margolskee DJ, Bnntinx A, Panwels RA, van der Strafen ME: MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human. Am Rev Respir Dis 144 (1991) 617-621.
78. Kirsch CM, Payan DC, Wang MYS, Dolilman JG, Blake VA, Pétri MA, Offenbcrger J, Goetzl EJ, Gold \VM: Effect of eicosapentaenoic acid in asthma. Clin. Allergy 18 (1988) 177-187.
79. Knapp HR, FitzGerald GA: The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med 320 (1989) 1037-1043.
80. Koch T, Dimcker HP, Rosenkranz S, Nenliof H, van Ackern K: Alterations of filtration coefficients in pulmonary edema of different pathogenesis. J Appl Physiol 73 (6) (1992) 2396-2402.
81. Koch T, Dimcker HP, Klein A, Schlotzer E, Peskar DM, van Ackern K, Nenliof H: Modulation of pulmonary vascular resistance and edema formation by short-term infusion of a 10% fish oil emulsion. Infusionstherapie Transfusionsmed 20(1993)291-300.
82. Koch T, Nenhof H, Dimcker HP, Stein A, Möscliet B, Scliönliarting M, van Ackern K: Influence of a PentoxifyllineAnalogue on the granulocyte-mediated pulmonary mediator release and vascular reaction. Circ Shock 40 (1993) 83-91.
83. Koch T, FisahnJ, Lutz F, van Ackern K, Nenhof H: Effects of Pseudomonas aeruginosa cytotoxin on pulmonary vascular tone and permeability. Pathophysiological aspects and therapeutic approaches. Clin Intensive Care 5 (1994) 225-231.
84. Köhler P, Nenhof H, Koch T, van Ackern K: Arachidonsäuremetabolite und Kapillarpermeabilität. In: Lawin P, Brüssel Th, Prien Th (Hrsg.) Jahrbuch der Anaesthesiologie und Intensivmedizin. Biermann-Verlag, Zülpich (1991) 131137.
85. Kola A, Klos A, Bautsch W, Krctschmar T, Kohl J: Functional activities of synthetic anaphylatoxic peptides in widely used biological assays. Clin Exp Iinmimol 88 (1992) 368-372.
86. Knbes P, Suzuki M, Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sei USA 88 (1991) 4651-4655.
87. Kubes P, Smith R, Grisham MD, Granger DN: Neutrophil-mediated proteolysis. Differential roles for Cathepsin G and Elastase. Inflammation 17 (1993) 321-333.
88. Kuniinoto F, Ogawa RM, Fujita T: Inhibition of lipid peroxidation improves survival rate of endotoxemia rats. Circ Shock 21 (1987) 15-22.
89. Leaf A: Cardiovascular effects of fish oils. Beyond the platelet. Circulation 82 (1990) 624-628.
90. Lee TH, Austen KF, Lcitch AC, Israel E, Robinson DR, Lewis RA, Corey EJ, Drazen JM: The effects of fish-oil-enriched diet on pulmonary mechanics during anaphylaxis. Am Rev Respir Dis 132 (1985) 1204-1209.
91. Lee GW, Tsoii AP, Chan H, Thomas J, Pétri K, Engiii EM, Allison AC: Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta RNA. Proc Natl Acad Sei USA 85 (1988) 1204-1208.
92. Lehr HA, Hübner C, Finckh B, Nolle D, Beisiegel U, Kolilschütter A, Messmer K: Dietary fish oil reduces leukocyte/endothelium interaction following systemic administration of oxidatively modified low density lipoprotein. Circulation 84 (1991) 1725-1731.
93. Lehr HA, Gnlilmann A, Nolle D, Keppler D, Messmer K: Leukotrienes as mediators in ischemia-reperfusion injury in a microcirculation model in the hamster. J Clin Invest 87 (1991)2036-2041.
94. Long WA, Rubin LJ: Prostacyclin and PGE1 treatment of pulmonary hypertension. Am Rev Respir Dis 136 (1987) 773-776.
95. Marra MN, Tliornton MB, Suable JL, Wilde CG, Scott R\V: Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibody HA-1A and E5. Crit Care Med 22 (1994)559-565.
96. McCleland P, Williams PS, Yacob M, Mostafa SM, Bone JM: Multiple organ failure - a role for plasma exchange? Intensive Care Med 16 (1990) 100-103.
97. McCloskey RV, Sträube RC, Sanders C, Smith SM, Smith CR: Treatment of septic shock with monoclonal antibody HA-1 A. A randomized, double-blind, placebo-controlled trial. CHESS trial study group. Ann Int Med 121 (1994) 1-5.
98. Mclntyre TM, Zimmerinan G A, Satoh K, Prescott SM: Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. J Clin Invest 76 (1985) 271-280.
99. Miete L, Cordclla-Miele D, Facchiano A, Mnkherjee AB: Novel anti-inflammatory peptides from the region of highest similarity between uteroglobin and lipocortin I. Nature 726 (1988) 335.
100. Minnear FL, Effect of bradykinin on lung vascular permeability in J Appl Physiol 55 (1983) 1079-1084.sheep. J Appl Physiol 55 (1983) 1079-1084.
101. A/0//OV RG, MannickJA, Rodrick ML: Cytokines, sepsis and immunomodulation. Br J Surg 80 (1993) 289-297.
102. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991) 109-42.
103. \03.Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329 (1993) 2002-2012.
104. W4.Montalescot G, Lowcnstein E, Oglctree ML, Create EM, Robinson DR, Hartl K, Zapol WM: Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep. Circulation 82 (1990) 1765-1777.
105. Moore JM, Earnest MA, DiSimone AF, Abttmrad NN, Fletcher JR: A PAF receptor antagonist, BN 52021, attenuates thromboxane release and improves survival in lethal canine endotoxemia. Circ Shock 32 (1991) 53-59.
106. A/ora/; P, Beasley H, Gorrell A, Martin E, Gribling P, Fuchs H, Gillett N, Burton LE, Caras IW: Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol 149 (1992) 17361743.
107. Morbidity and Mortality weekly Report: Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR 39 (1990) 31-34.
108. 2 integrins of rat neutrophils in complement-and oxygen radical-mediated acute inflammatory injury. J Immunol 148 (1992) 18471857.
109. \Q9.Nathan C, Hibbs JB Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 3 (1991) 65-70.
110. Needleinan, I', Raz A, Minkcs MS, Ferrendelli JA, Sprecher H: Triene prostaglandins: Prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sei US A 76 ( 1979) 944-948.
111. lU.NeiiliofH, Scegcr W, Wolf 11RG, Hall J, Crampical B, Neumann C: Acute increase in pulmonary vascular resistance induced by circulating fibrin monomers, mediated by pulmonary thromboxane A2 generation. Eur J Resp Dis 64(1984)473-482.
112. \l2.NeiiliofH, Seeger W, WolfHRD: Generation of mediators by limited proteolysis during blood coagulation and fibrinolysis - its pathogenetic role in the adult repiratory distress syndrome (ARDS). Resuscitation 14 (1986) 23-32.
113. l\3.NenliofH: Zur Rolle der Mediatoren bei der Sepsis. Intensivmed. 26 (1989)3-9.
114. IH.Ngityen T, Brunson D, Crespi CL, Penman BW, Wislinok JS, Tanenbawn SR: DNA damage and mutation in human cells exposed to nitric oxide in vitro. Biochemistry 89 (1992) 3030-3034.
115. \l5.Niederinan MS, Fein AM: Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia: a common clinical sequence. Clin Chest Med 11 (1990) 663665.
116. \\6.Novotny MJ, Laitghlin Mil, Adams HR: Evidence for lack of importance of oxygen free radicals in Escherichia coli endotoxinemia in dogs. Am J Physiol 254 (1988) H954H962.
117. Nnythick JKS, Goris RJA, Redl H, Schlag G, Munster PJJ: Posttraumatic complications and inflammtory mediators. Arch Surg 121 (1986) 886-890.
118. llS.Oettinger W, Berger D, Beger HG: The clinical significance of prostaglandins and thromboxane as mediators of septic shock. Klin Wschr 65 (1987) 61-68. 119.
119. O///550/1 K, Bjork P, Bcrgenfelilt M, Hagenwn R, Thompson RC: lnterleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348 (1990) 550-552.
120. Palmer RJ, Pollock JS, Moncada S: Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor. Nature 327 (1987) 524-526.
121. Pappen D, Busch T, Wandowski K, Radcnnacher P, Rossaint R: Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 82 (1995) 1507-1511.
122. Parillo JE: Managment of Septic Shock: Present and Future. Ann Intern Med 115 (1991):491-493.
123. \23.Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P: Effects of a nitric oxide synthesis inhibitor in humans with septic shock. Cardiovasc Res 28 (1994) 34-39.
124. Rabinovici R, Yeh CG, Hillegass LM, Griswold DE, DiMartino MJ, Vernick J, Fang KLL, Feuerstein G: Role of complement in endotoxin/platelet-activating factor-induced lung injury. J Immunol 149 (1992) 1744-1750.
125. Radomski MW, Palmer RM, Moncada S: An L-arginine/nitric oxide pathway present in human platelets regulates aagregation. Proc Natl Acad Sei USA. 87 (1990) 5193-7.
126. Ratnoff WD, Mattlmy MA, Wong MY, Ito Y, Vu KH, Wiener-Kronisli J, Goetzl EJ: Sulfidopeptide-leukotriene peptidases in pulmonary edema fluid from patients with the adult respiratory distress syndrome. J Clin Immunol 8 (1988) 250-258.
127. \21.Redl H, Schlag G: Pathpphysiology of multiple organ failure - inflammatory factors and mediators. Clin Intensive Care 2 (1991) 16-27.
128. l28.ReidyJJ, Ramsay G: Clinical trials of selective decontamination of the digestive tract: Review. Crit Care Med 18 (1990) 1449-1456.
129. Richards IM, Griffin RL, OostveenJA, Morris J, Wislika DG, Diinn CJ: Effect of the selective leukotriene B4 antagonist U-75302 on antigen-induced bronchopulmonary eosinophilia in sensitized guinea piss. Am Rev Respir Dis 140 (1989) 1712-1718.
130. Allison RC, Parker JC, Taylor AE: Effects of histamine, serotonin and norepinephrin on circulation of dog lungs. J Appl Physiol 57 (1984) 223-232.
131. \3l.Rossaint R, Gerlach H, Schmidt-Rnhnkc H, Pappert D, Lewandowski K, Stendel W, Falke K: Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 107 (1995) 1107-1115.
132. \32.Scliade UF: Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 31:171-181, 1990.
133. lll.Scliirmer \VJ, Schirmer JM, Naff CD, Fry DE: Systemic complement activation produces hemodynamic changes characteristic of sepsis. Arch Surg 123 (1988) 316-321.
134. Schneider J: Prophylactic and curative effects of recombinant human Superoxide dismutase in lethal rat endotoxemia. Drug Res 38 (1992) 1381-1385.
135. \35.Seeger W, Mcngcr M, \Valmrath D, Decker G, Grimminger F, Nculiof H: Arachidonic acid lipoxygenase pathways and increased vascular permeability in isolated rabbit lungs. Am Rev Respir Dis 136 (1987) 964-972.
136. \36.Seeger W, Nculiof H, Hall J, Roka L: Pulmonary vasoconstrictor response to soluble fibrin in isolated lungs: possible role of thromboxane generation. Circ Res 62 (1988) 651659.
137. \31.Scegcr \V, Obernitz R, Thomas M, Walmratli D, Holland IB, Griniminger F, Ebcrspiichcr D, Hugo F, Snttorp N, Bhakdi S: Lung vascular injury after administration of viable hemolysin-forming Escherichia coli in isolated rabbit lungs. Am Rev Respir Dis 143 (1991) 797-805.
138. Shocmaker WC, Appel PL, Kram HB, Bishop MH, Abraham E: Sequence of physiologic patterns in surgical septic shock. Crit Care Med 21 (1993) 1876-1889.
139. Sibbald VJ, Fox G, Martin C: Abnormalities of vascular reactivity in the sepsis syndrome. Chest 100 (1991) 155-159.
140. Siebeck M, KohlJ, Endrcs S, Spannagl M, Machlcidt \V: Delayed treatment with platelet activating factor receptor antagonist web 2086 attenuates pulmonary dysfunction in porcine endotoxic shock. J Trauma 37 (1994) 745-751.
141. l4\.Simoponlos AP: Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 54 (1991)538-463.
142. Smedegard G,Hugli TE: Endotoxin-induced shock in the rat. A role for C5a. Am J Path 135 (1989) 489497.
143. \43.Spies CD, Reinhan K, Wilt I, Mcicr-Hellinann A, Hanneinann L, Bredle DL, Scliaffartzik W: Influence of Nacetylcysteine on indirect indicators of tissue oxygénation in septic shock patients: results for a prospective, randomized, double-blind study. Crit Care Med 22 (1994) 1738-1746.
144. Starnes HFJr, Pearce MK, Tewari A, YimJH, ZouJ-C, Abrams JS: Anti-IL6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-a challenge in mice. J Immunol 145 (1990) 4185-4191.
145. 145.5fc/;i B, Pfcnninger E, Grünen A, Schmilz JE, Hiidde M: Influence of continuous haemofiltration on haemodynamics and central blood volume in experimental endotoxic shock. Intensive Care Med 16 (1990) 494-499.
146. \46.Stcphenson AH, Lonigro AJ, Hyers TM, Webster RO, Fowler AA: Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. Am Rev Respir Dis 138 (1988) 714-719.
147. Stevens JH, O'Haiiley PT, ShapiroJM, M Him FG, Satoh PS, CollinsJA, Raffin TA: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 77 (1986) 1812-1815.
148. l48.Sitcliner U, Senftleben U, Felbinger T: Nichtenergetische Aspekte der Ernährung. In: Lawin P, Peter K, Prien Th: Intensivmedizin 1995, Praxis der Intensivbehandlung, Bd. 85, Georg Thieme Verlag Stuttgart, New York (1995) 178-205.
149. \49.Sutcr PM, Domeniglietti G, Schallen M-D, Laverriere M-C, Ritt R, Pcttcr C: N-acetylcysteine enhances recovery from acute lung injury in man. Chest 105 (1994) 190-194.
150. Suter PM, PittetJ-F, Masonye Ph, Morel DR: Xanthinederivates pentoxifylline and HWA 138 attenuate cardiocirculatory and pulmonary failure secondary to endotoxin in sheep. Circ Shock 34 (1991) 140-141.
151. \5l.Snttorp N, Galnnos C, Nenhof H: Endotoxin alters arachidonate metabolism in pulmonary endothelial cells. Am J Physiol 253 (1987) C384-C391.
152. Tlic National Coiiiinitec for the Evaluation of Centoxin: The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. Arch Int Med 154 (1994)2484-2491.
153. Tracey KJ, Fong Y, Hesse DC, Monogue KR, Lee AT, Kiio GC, Lowry SF, Ceraini A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330 (1987) 662-664.
154. Urakaze M, llamazaki T, Makiita M, Ibuki F, Kobayashi S, Yano S, Kiniwgai A: Infusion of fish oil emulsion: effects on platelet aggregation and fatty acid composition in phospholipids of plasma, platelets, and red blood cell membranes in rabbits. Am J Clin Nutr46 (1987) 936-940.
155. Van Saene HKF, Stoutenbeek CC, Stollcr JK: Selective decontamination of the digestive tract in the intensive care unit: Current status and future prospects. Crit Care Med 20 (1992) 691-703.
156. Waclitfogel YT, Pixley RA, Kucich U, Abrams W, Weinbauin G, Schapira M, Column R\V: Purified plasma factor Xlla aggregates human neutrophils and causes degranulation. Blood 67 (1986) 1731-1737.
157. HWJ CJ, Carey PD, Cook DJ, Dechard DE, Fowler AA, Siigeniwn HJ: Anti-CD18 antibody attenuates neutropenia and alveolar-capillary membrane injury during gramnegative sepsis. Surgery 110 (1991) 205-12.
158. Weber PC: Fish oil fatty acids and cardiovascular function: epidemiology and biochemical mechanisms. Bioclicin. Soc. Trans. 18 (1990):1045-1049.
159. Weisman HF, Bartow T, Leppo MK, Marsh HCJ, Carson GR, Condna MF, Boyle MP, Roux KH, Weisfehlt ML, Fearon DT: Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249 (1990) 146-151.
160. Weinberg E, Liindberg JM, Rudehill A: Inhibitory effects of diclofenac on the endotoxin shock response in relation to endothelin turnover in the pig. Acta Anaesth Scand 39 (1995) 50-59.
161. Welter HF, Tlielter D, Siebeck M, Wiesinger H, Elster U, Joclnim M: Study on the treatment of shock lung with superoxide dismutase (SOD) and Cl-inactivator (Cl-INA). Chir Forum 1985 (1985) 63-67.
162. Wenzel R, Bone RC, Fein A, Quenzer R, ShentagJ, Gorelick KJ: Results of a second double-blind, randomized, controlled trial of anti-endotoxin antibody E5 in gram-negative sepsis. Program and Abstracts of the Thirty-First Interscience Conference of Antimicrobial Agents and Chemotherapy 1991:294.
163. Wetzel RC: Aerolized prostacyclin. In search of the ideal pulmonary vasodilator (Editorial). Anesthesiolosy 82 (1995)1315-1317.
164. Wolfe RA, Dasta JF: Use of nitric oxide synthetase inhibitors as a novel treatment for septic shock. Ann Pharmacother 29 (1995) 36-46.
165. Yii M, Tomasa G: A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 21 (1993) 1635-1642.
166. Zabcl P, Walter DT, Sclionliarting MM, Schade FU: Oxpentifylline in endotoxemia. Lancet 2 (1989) 1474-1477.
167. 4 receptor antagonist in porcine septic shock. Eicosanoids 4 (1991) 169-175.
168. Ziegler EJ, McCntclian JA, FiererJ, et al:. Treatment of Gram-negative bacteremia and shock with human antiserum to mutant Escherichia coli. N Engl J Med 307 (1982) 12251230.
169. \69.Zieglcr EJ, Fisher CJ Jr, Sprung CL, Sträube RC, Sadoff 1C, Fonlkc GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, Alien IE, Berger HJ, Knatternd GL, LoBnglio AF, Smith CR, HA-1A Sepsis Study Group: Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 324 (1991)429-436.
170. \70.Z\visslcr B, Weite M, Messmcr K: Effects of inhaled prostaglandin PGI2 as compared to inhaled nitric oxide (NO) on right ventricular performance in hypoxic pulmonary vasoconstriction. J Cardiothorac Vase Anesth 9 (1995) 283-89.
171. \ll.ZwisslerB, Wehe M, Messmer K: Inhalation of vasodilatory drugs or gases. Current Opinion Anesthesiol 8 (1995) 557-64.